CoChat

Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study⋆

Yee, Karen, Papayannidis, Cristina, Vey, Norbert, Dickinson, Michael J., Kelly, Kevin R., Assouline, Sarit, Kasner, Margaret, Seiter, Karen, Drummond, Mark W., Yoon, Sung-Soo, Lee, Je-Hwan, Blotner, Steven, Jukofsky, Lori, Pierceall, William E., Zhi, Jianguo, Simon, Silke, Higgins, Brian, Nichols, Gwen, Monnet, Annabelle, Muehlbauer, Susanne, Ott, Marion, Chen, Lin-Chi, Martinelli, Giovanni · 2021 · Leukemia Research
Cited by 47

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

The prognosis remains poor for patients with relapsed or refractory (r/r) acute myeloid leukemia; thus, novel therapies are needed. We evaluated idasanutlin-a new, potent murine double minute 2 antagonist-alone or with cytarabine in patients with r/r acute myeloid leukemia, de novo untreated acute myeloid leukemia unsuitable for standard treatment or with adverse features, or secondary acute myeloid leukemia in a multicenter, open-label, phase 1/1b trial. Primary objectives were to determine the maximum tolerated dose (MTD) and recommended dose for expansion (RDE) and characterize the safety profile of idasanutlin monotherapy and combination therapy. Clinical activity and pharmacokinetics were secondary objectives. Two idasanutlin formulations were investigated: a microprecipitate bulk powder (MBP) and optimized spray-dried powder (SDP). Following dose escalation, patients (N = 122) received idasanutlin at the RDE in the extension cohorts. No formal MTD was identified. Idasanutlin was tolerable alone and in combination with cytarabine. The RDE was determined as 600 mg twice a day for the MBP formulation and 300 mg twice a day for the SDP formulation. Adverse events were mostly grade 1/2 (76.2 %). The most common any-grade adverse events were gastrointestinal (including diarrhea [90.2 %]). The early death rate across all patients was 14.8 %. Plasma idasanutlin exposure was dose related. In TP53 wild-type patients, composite complete remission rates were 18.9 % with monotherapy and 35.6 % with combination therapy. Based on these results, idasanutlin development continued with further investigation in the treatment of acute myeloid leukemia. ClinicalTrials.gov: NCT01773408.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.leukres.2020.106489

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 47

Metadata

Authors
Yee, K., Papayannidis, C., Vey, N., Dickinson, M. J., Kelly, K. R., Assouline, S., Kasner, M., Seiter, K., Drummond, M. W., Yoon, S.-S., Lee, J.-H., Blotner, S., Jukofsky, L., Pierceall, W. E., Zhi, J., Simon, S., Higgins, B., Nichols, G., Monnet, A., Muehlbauer, S., Ott, M., Chen, L.-C., & Martinelli, G.
Venue
Leukemia Research
Publisher
Elsevier BV
Published
2021-01
Volume
100
Pages
106489
ISSN
0145-2126 (ISSN-L)
OpenAlex
W3106887103
Cited by
47
References
5
FWCI
3.78
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study⋆. https://app.cochat.ai/papers/10.1016/j.leukres.2020.106489
The paper
Yee, K., Papayannidis, C., Vey, N., Dickinson, M. J., Kelly, K. R., Assouline, S., Kasner, M., Seiter, K., Drummond, M. W., Yoon, S.-S., Lee, J.-H., Blotner, S., Jukofsky, L., Pierceall, W. E., Zhi, J., Simon, S., Higgins, B., Nichols, G., Monnet, A., . . . Martinelli, G. (2021). Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study⋆. Leukemia Research. https://doi.org/10.1016/j.leukres.2020.106489

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.